Comparative Pharmacology
Head-to-head clinical analysis: VEETIDS 125 versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEETIDS 125 versus VEETIDS 500.
VEETIDS '125' vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
125 mg orally twice daily for 5-10 days.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic